Medicare drug spending will slow due to IRA price negotiations, CMS...
Medicare spending on prescription drugs is expected to grow at a slower rate between 2028 and 2033 as a result of drug pricing provisions in the Inflation Reduction Act, a report by members of CMS' ...
View ArticleEndpoints Livestream: ACIP and the future of vaccines
Today on Post-Hoc Live, I'll be joined by senior editor Zachary Brennan and pharma reporter Max Bayer for a wide-ranging discussion about the remade Advisory Committee on Immunization Practices and how...
View ArticleNovartis strikes cardiovascular discovery deal with Flagship’s ProFound
Novartis has signed up proteomics specialist ProFound Therapeutics to pinpoint “previously unknown” proteins to be investigated as cardiovascular drugs and drug targets in a $25 million upfront deal....
View ArticleVor Bio bounces back with RemeGen autoimmune deal, $175M private placement
In an unexpected turn of events, Vor Bio is back on the fundraising trail and shifting focus to autoimmune disease, less than two months after it seemed to be at the end ...
View ArticleBharat, GSK to cut malaria vaccine price; Emergent's US stockpile deal expands
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bharat Biotech and GSK said they will reduce the price of their ...
View ArticleHandspring Health raises $12M to provide more complex care for youth
Youth virtual mental health startup Handspring Health just raised $12 million, Endpoints News has learned exclusively. Cobalt Ventures led the Series A round, with contributions from NextView Ventures,...
View ArticleWhy Commure, one of healthcare's most deal-hungry startups, plans to buy more...
Commure, one of the buzziest healthcare startups backed by General Catalyst, is hunting for more startups to buy — AI scribes included. Commure has been on a shopping spree over the past few years,...
View ArticleOpus, Viatris say presbyopia drug succeeds in Phase 3
Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year. The phentolamine ophthalmic solution 0.75% program ...
View ArticleEdgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M...
Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data...
View ArticleAltimmune posts mixed results for incretin drug in MASH; stock is halved
Altimmune said its experimental therapy for a serious fatty liver disease hit one key endpoint but not the other in a Phase 2b study. The biotech’s shares {$ALT} tanked after the ...
View ArticleCDC vaccine panel votes to remove thimerosal from flu shots
Clinicians and infectious disease specialists clashed with the majority of the CDC’s remade vaccine advisory committee on Thursday, arguing that the panel’s debate over an ingredient in a small number...
View ArticleJudge says CVS Caremark owes $95M in false claims case
A Pennsylvania federal judge ruled that CVS Caremark owes the federal government $95 million in a case that accused the pharmacy benefit manager of conduct that caused Medicare to overpay for...
View ArticleAI scribes are evolving
For so long, AI scribes pitched healthcare providers on the promise of reducing burnout. But lately, we’ve been hearing a different pitch: that scribes can be used to make billing easier. Take Abridge,...
View ArticleGilead ends RSV antiviral trials after low incidence rates
Gilead Sciences has terminated two Phase 2 studies of an RSV treatment candidate called obeldesivir. The California biotech ended a trial of the oral tablet in non-hospitalized adults and another study...
View ArticleA dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint
For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life Sanofi's interest in acquiring the commercial-stage drugmaker. Blueprint had almost lost out on a $9.5...
View ArticleBill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys...
→ Hervé Hoppenot is handing the CEO post at Incyte to Bill Meury after 11 years leading the Delaware drugmaker. Endpoints News caught up with Hoppenot and Meury on their last and first days on ...
View ArticleAlphabet’s Calico inks $25M licensing deal for Mabwell’s IL-11 programs
Longevity biotech Calico is spending $25 million in cash to license therapeutic candidates targeting the interleukin-11 protein from China’s Mabwell. Calico will get exclusive global rights to a...
View ArticleFDA head Makary's intervention attempt on KalVista raises concerns
FDA Commissioner Marty Makary’s unsuccessful attempt to intervene in an ongoing drug review, as described by multiple agency sources, raises further concerns about the regulator under its new...
View ArticleInnovent brings a new mechanism to obesity market with China approval
Innovent said on Friday that its obesity medicine mazdutide has been approved in China, becoming the first dual GLP-1/glucagon agonist to be greenlit for the disease anywhere in the world. ...
View ArticleBioCryst sells Orladeyo business in Europe; UCB gets a Phase 3 win for Fintepla
Plus, news about XOMA Royalty, Turnstone Biologics, CorMedix, the Novo Nordisk Foundation, Achieve Life Sciences and Cidara Therapeutics: BioCryst sells Orladeyo business in Europe: The company will...
View Article